Oncomedicine 2017; 2:61-65. doi:10.7150/oncm.17910 This volume
Short Research Paper
Concurrent Capecitabine and Radiation Therapy for High-risk Primary Breast Cancer
1. University of Arizona, Tucson, Arizona, United States;
2. Tucson Medical Center, Surgery, Tucson, Arizona, United States
Goyal U, Skrepnik T, Davuluri R, Ley MB, Chalasani P, Viscusi RK, Lebeau LG, Livingston RB, Famoso J, Gonzalez VJ. Concurrent Capecitabine and Radiation Therapy for High-risk Primary Breast Cancer. Oncomedicine 2017; 2:61-65. doi:10.7150/oncm.17910. Available from http://www.oncm.org/v02p0061.htm
Introduction: Data is limited for concurrent capecitabine-radiotherapy (CCRT) in primary breast cancer. We evaluated outcomes and toxicities of patients at high risk of locoregional recurrence receiving adjuvant CCRT.
Methods: Ten non-metastatic breast cancer patients receiving concurrent treatment were reviewed retrospectively. Capecitabine was given during and after radiation. Toxicity was reviewed using weekly on-treatment visit and follow-up notes.
Results: All patients had stage II-III disease. Four patients had grade 3 skin toxicity during radiation. Capecitabine and RT-related toxicity breaks occurred for 5 and 0 patients, respectively. At 1-month follow-up, 9 patients recovered from acute toxicities sufficiently to start adjuvant capecitabine. At 25 months median follow-up, 1 patient had synchronous local recurrence and distant metastasis (DM), while 3 patients had DM only.
Conclusions: Use of CCRT for breast cancer was associated with significant acute grade 3 dermatitis, however, all patients successfully completed their radiation course without interruption.
Keywords: breast cancer, capecitabine, high-risk, radiation